Article对《最高人民法院知识产权法庭裁判要旨摘要（2023）》所涉药品专利链接诉讼案件的解读（二）然而，如何适用这些规定处理药品专利纠纷案件，实践中争议很大。ChinaIntellectual PropertyAnJie Broad Law Firm
Article2024年専利復審・無効審判の典型事例判決要点集（二）【事件番号】1F516906 チップ式熱交換器及びインバーターエアコン...ChinaIntellectual PropertyKangxin
Article汉坤 • 观点 | 从药械产品全生命周期视角解读License-in/out许可交易项目合作条款要点创新药械的研发，是一场依托于企业团队的专业技术实力、满载着从业人员的热情与信念、又充满了各种冒险与挑战的旅程，结天时地利人和
Article转用发明创造性浅析专利审查指南第二部分第四章第4.4节规定了转用发明创造性判断的考量因素...ChinaIntellectual PropertyCCPIT Patent and Trademark Law Office
Article精细化辩护，不放过任何可能的有利辩点 ——王某某非法经营案二审无罪辩护发回重审办案手记王某某非法经营案件，一审被告人违心作出有罪供述，同案犯及证人的供述及证言对被告人极为不利，一审律师做罪轻辩护，一审判决认定王ChinaFood, Drugs, Healthcare, Life SciencesDeHeng Law Offices
ArticleMeasures For Supervision And Administration Of Online Sales Of Drugs: Analysis Of Key Aspects And ImpactsFast-growing e-commerce has changed lifestyles and invented new ways of consumption, amid which demand has rapidly increased for Internet-based medical services such as online drug sales...ChinaFood, Drugs, Healthcare, Life SciencesHan Kun Law Offices
Article《生命健康法律期刊》第三期发布China's pharmaceutical and life sciences regulatory landscape underwent significant transformation in 2026, with major policy updates spanning drug approval processes, medical device quality standards, and healthcare facility management. The National Medical Products Administration introduced priority review pathways for chemical APIs and updated cosmetics registration requirements, while new medical device production standards took effect nationwide. ChinaFood, Drugs, Healthcare, Life SciencesJincheng Tongda & Neal
Article医药许可与BD合作交易近期常见争议及对交易文件起草的启示随着资本市场退出渠道的收紧、美元基金的持续观望，以及医药领域投融资市场前些年在估值上较为激进的安排，2022年起至今生物医药行业投融ChinaFood, Drugs, Healthcare, Life SciencesAnJie Broad Law Firm
ArticleSRS v. Alexion药品许可诉讼案评析——兼论中国创新药企BD合同的风险防控与条款设计特拉华州衡平法院在SRS诉Alexion案中，就跨境医药BD交易中的里程碑付款争议、商业合理努力义务及预期损失量化作出了详尽裁判。本文深入剖析该案判ChinaCorporate/Commercial LawJincheng Tongda & Neal
ArticleHan Kun • Opinion | The Spring Of Traditional Chinese Medicine? From The "Special Provisions On The Registration And Administration Of Traditional Chinese Medicines", The Characteristic Marketing Evaluation System Of Traditional Chinese MedicineIn recent years, our country has been vigorously supporting the inheritance, innovation and development of traditional Chinese medicine. In 2019...ChinaFood, Drugs, Healthcare, Life SciencesHan Kun Law Offices
ArticleHan Kun Opinion | Breaking News: 10 Questions And Answers On Pharmaceutical Anti-Corruption In 2023Recently, a nationwide campaign to combat corruption in the pharmaceutical sector has been underway in full swing, attracting widespread attention from the industry...ChinaFood, Drugs, Healthcare, Life SciencesHan Kun Law Offices
Article关于我国药品专利权期限补偿制度的一些思考和建议摘要：药品专利权期限...ChinaIntellectual PropertyCCPIT Patent and Trademark Law Office
ArticleConsiderations On The Protection Of Remdesivir Under Trademark LawDuring the period of outbreak of COVID-19, Remdesivir, which has not entered into Chinese market as a new drug, has attracted public attention. However, since February 3, 2020 to date, there have been...ChinaIntellectual PropertyCCPIT Patent and Trademark Law Office
ArticleHan Kun • Opinion | Research On Urban Customized Commercial Medical InsuranceIn order to promote the construction of a healthy China, our country has continuously strengthened the top-level design of the universal medical security system.ChinaInsuranceHan Kun Law Offices
Article论我国新药相关发明专利权期限补偿法律规范的解释与适用上述孙文和蒋文均聚焦于《专利审查指南》第五部分第九章第3.5节“新药相关技术方案应当以国务院药品监督管理部门批准的新药的结构、组成及其含量，批准的生产工艺和适应症为准。指定权利要求未包括获得上市许可的新药相关技术方案的，不予期限补偿”的规定，进行分析和论证，然而ChinaIntellectual PropertyAnJie Broad Law Firm
Article2025年度广告合规洞察：监管新规下的合规之道自迈入2025年以来，伴随广告行业新业态、新模式、新技术的不断涌现，我国广告监管也迎来了体系化升级，从广告法系列执法指南的出台...ChinaMedia, Telecoms, IT, EntertainmentFangda Partners
Article新时代医药反腐历程及重点罪名简析在此大背景下，我们团队根据近期观察与研究，从医药行业及法律行业的综合角度出发，对此次医药反腐行动的发展进程以及可能涉及的重点 ChinaFood, Drugs, Healthcare, Life SciencesAnJie Broad Law Firm
Article2020年反垄断十大案例之安杰盘点2020年4月20日，市场监管总局公布上海明察哲刚管理咨询有限公司与环胜信息技术（上海）有限公司新设合营企业案的简易案件公示表，表明市监öChinaAntitrust/Competition LawAnJie Broad Law Firm
